Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Lapatinib |
| Synonyms | |
| Therapy Description |
Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Lapatinib | Tykerb | FMM | EGFR Inhibitor (Pan) 45 HER2 (ERBB2) Antibody 36 | Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB2 Y803N | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) Y803N demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). | 18413839 |
| ERBB2 V773A | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346). | 22046346 |
| ERBB2 L755S | breast cancer | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed breast epithelial cells expressing ERBB2 (HER2) L755S were resistant to Tykerb (lapatinib) in culture (PMID: 31135266). | 31135266 |
| ERBB2 L755_T759del | breast cancer | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were resistant to treatment with Tykerb (lapatinib), resulting in decreased growth inhibition (PMID: 23220880). | 23220880 |
| ERBB2 S310Y | colorectal cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). | 26243863 |
| ERBB2 T798M | Her2-receptor positive breast cancer | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973). | 23948973 |
| ERBB2 Q709L | Advanced Solid Tumor | predicted - sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Q709L demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325). | 30449325 |
| ERBB2 over exp | stomach cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637). | 18774637 |
| ERBB2 L726F | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) L726F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). | 18413839 |
| ERBB2 G776delinsVC | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 G776delinsVC | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Tykerb (lapatinib) in culture (PMID: 30527195). | 30527195 |
| ERBB2 amp | colorectal cancer | decreased response | Lapatinib | Preclinical - Pdx | Actionable | In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355). | 26296355 |
| ERBB2 S310F | urinary bladder cancer | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884). | 24971884 |
| ERBB2 G776delinsLC | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsLC were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 T862A | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346). | 22046346 |
| ERBB2 amp | esophagus adenocarcinoma | no benefit | Lapatinib | Phase III | Actionable | In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in esophagus adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478). | 26628478 |
| ERBB2 R896C | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880). | 23220880 |
| ERBB2 V842I | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V842I were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 L786V | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L786V were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 N857S | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N857S in culture (PMID: 22046346). | 22046346 |
| ERBB2 L869R | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 V777L | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). | 23220880 |
| ERBB2 L663P | Advanced Solid Tumor | predicted - sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L663P demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325). | 30449325 |
| ERBB2 amp | breast cancer | decreased response | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Tykerb (lapatinib) demonstrated decreased phosphorylation of Erbb2 (her2) and Akt, however, after 4-8 hours, Akt-driven Rictor showed upregulation, thereby resulting in a decreased treatment response (PMID: 27197158). | 27197158 |
| ERBB2 G776delinsVV | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVV were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 D277H ERBB2 S310F | urinary bladder cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884). | 24971884 |
| ERBB2 over exp PIK3CA H1047R SRC over exp | urinary bladder cancer | no benefit | Lapatinib | Preclinical - Pdx | Actionable | In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481). | 26270481 |
| ERBB2 G778_P780dup | Her2-receptor positive breast cancer | predicted - resistant | Lapatinib | Case Reports/Case Series | Actionable | In a clinical case study, ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) was identified in a patient with ERBB2 (HER2)-positive breast cancer at the time of disease progression while on Tykerb (lapatinib) treatment (PMID: 31980423). | 31980423 |
| ERBB2 R678Q | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). | 23220880 |
| ERBB2 G660D | Advanced Solid Tumor | predicted - sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G660D demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325). | 30449325 |
| ERBB2 pos PIK3CA mut | Her2-receptor positive breast cancer | decreased response | Lapatinib | Clinical Study - Cohort | Actionable | In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 28177460). | 28177460 |
| ERBB2 L869R | breast cancer | resistant | Lapatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369). | 27900369 |
| ERBB2 G660R | Advanced Solid Tumor | predicted - sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G660R demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325). | 30449325 |
| ERBB2 amp | gastroesophageal junction adenocarcinoma | no benefit | Lapatinib | Phase III | Actionable | In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastroesophageal junction adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478). | 26628478 |
| PIK3CA G1049R | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007). | 26627007 |
| ERBB4 R393W | melanoma | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of melanoma cells harboring ERBB4 R393W in culture (PMID: 19718025). | 19718025 |
| ERBB2 D769Y ERBB2 amp | Her2-receptor positive breast cancer | resistant | Lapatinib | Preclinical - Pdx | Actionable | In a preclinical study, a breast cancer patient-derived xenograft (PDX) model with ERBB2 (HER2) amplification and ERBB2 D769Y was refractory to treatment with Tykerb (lapatinib) (PMID: 30301790). | 30301790 |
| ERBB2 G776delinsVC | lung non-small cell carcinoma | no benefit | Lapatinib | Clinical Study | Actionable | In a retrospective analysis, Tykerb (lapatinib) treatment resulted in an objective response rate of 0% (0/1) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195). | 30527195 |
| PIK3CA Q546K | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007). | 26627007 |
| ERBB4 E317K | melanoma | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E317K in culture (PMID: 19718025). | 19718025 |
| ERBB2 L755S | Her2-receptor positive breast cancer | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) in ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 28487443). | 28487443 |
| ERBB2 S653C | urinary bladder cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884). | 24971884 |
| ERBB2 G776delinsVC ERBB2 C805S | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC and an acquired ERBB2 (HER2) C805S were resistant to Tykerb (lapatinib) in culture (PMID: 30527195). | 30527195 |
| ERBB2 L755S | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346). | 22046346 |
| ERBB2 L755S | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L755S were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 G778_S779insLPS | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 L768S | breast cancer | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). | 27697991 |
| ERBB2 D769Y | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) D769Y were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 D769Y | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880). | 23220880 |
| ERBB2 V777L | Advanced Solid Tumor | conflicting | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V777L were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 V777L | Advanced Solid Tumor | conflicting | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346). | 22046346 |
| ERBB2 over exp | Her2-receptor positive breast cancer | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453). | 27450453 |
| ERBB2 S783P | Advanced Solid Tumor | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) S783P were resistant to Tykerb (lapatinib) in culture (PMID: 18413839). | 18413839 |
| ERBB2 H878Y | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) H878Y in culture (PMID: 22046346). | 22046346 |
| ERBB2 T798I | lung cancer | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247). | 25238247 |
| ERBB2 D769H | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). | 23220880 |
| ERBB2 amp | gastric adenocarcinoma | no benefit | Lapatinib | Phase III | Actionable | In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastric adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478). | 26628478 |
| ERBB2 T798I | Advanced Solid Tumor | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247). | 25238247 |
| PIK3CA N345K | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007). | 26627007 |
| ERBB2 G778_P780dup | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P80dup were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 G778_P780dup | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) were resistant to Tykerb (lapatinib) in culture (PMID: 30527195). | 30527195 |
| ERBB2 D769N | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited growth of transformed cells expressing ERBB2 (HER2) D769H in culture (PMID: 31588020). | 31588020 |
| ERBB2 amp SRC E527K | gastroesophageal junction adenocarcinoma | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, an ERBB2 (HER2)-amplified gastroesophageal cancer cell line initially sensitive to treatment with Tykerb (lapatinib) in culture developed resistance and was subsequently found to have acquired a secondary drug resistant mutation, SRC E527K (PMID: 25350844). | 25350844 |
| ERBB2 T733I | Advanced Solid Tumor | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) T733I demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839). | 18413839 |
| ERBB2 P780L | Advanced Solid Tumor | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) P780L demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839). | 18413839 |
| ERBB2 L869R | lung adenocarcinoma | predicted - resistant | Lapatinib | Case Reports/Case Series | Actionable | In a clinical case study, ERBB2 (HER2) L869R was identified in the lymph node metastasis from a lung adenocarcinoma patient that progressed on Tykerb (lapatinib) therapy (PMID: 27900369). | 27900369 |
| ERBB2 K753E | breast cancer | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Tykerb (lapatinib) in culture (PMID: 27697991). | 27697991 |
| ERBB2 V659E | Advanced Solid Tumor | predicted - sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V659E demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325). | 30449325 |
| ERBB2 L726F | breast cancer | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L726F demonstrated resistance to Tykerb (lapatinib) in both culture and xenograft models (PMID: 25435280). | 25435280 |
| ERBB2 wild-type | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346). | 22046346 |
| PIK3CA E545K | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007). | 26627007 |
| PIK3CA H1047L | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007). | 26627007 |
| ERBB2 R678Q | Advanced Solid Tumor | predicted - sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) R678Q demonstrated decreased cell proliferation and reduced survival when treated with Tykerb (lapatinib) in culture (PMID: 30449325). | 30449325 |
| ERBB2 G778_P780dup | breast cancer | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Tykerb (lapatinib) (PMID: 23220880). | 23220880 |
| ERBB2 G778_P780dup | breast cancer | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, breast epithelial cells expressing ERBB2 (HER2) G778_P780dup (reported as P780_Y781insGSP) were resistant to Tykerb (lapatinib) treatment in cell culture (PMID: 31980423). | 31980423 |
| ERBB2 Y772_A775dup ERBB2 C805S | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) and an acquired ERBB2 (HER2) C805S were resistant to Tykerb (lapatinib) in culture (PMID: 30527195). | 30527195 |
| ERBB2 G309A | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). | 23220880 |
| ERBB2 S310F | Advanced Solid Tumor | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cells expressing ERBB2 S310F in culture (PMID: 22908275). | 22908275 |
| ERBB4 E563K | melanoma | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E563K in culture (PMID: 19718025). | 19718025 |
| ERBB2 V773L | breast cancer | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). | 27697991 |
| ERBB2 V842I | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). | 23220880 |
| ERBB2 T798M | Advanced Solid Tumor | resistant | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346). | 22046346 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tykerb (lapatinib) in culture (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 amp | stomach cancer | sensitive | Lapatinib | Preclinical | Actionable | In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222). | 20179222 |
| ERBB4 R544W | melanoma | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) induced apoptosis in melanoma cells harboring ERBB4 R544W in culture (PMID: 19718025). | 19718025 |
| ERBB2 L755S ERBB2 amp | Her2-receptor positive breast cancer | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cell lines with ERBB2 (HER2) amplification and expressing ERBB2 L755S demonstrated decreased inhibition of ERBB2 (HER2) signaling and proliferation compared to cells expressing wild-type ERBB2 (HER2) following treatment with Tykerb (lapatinib) (PMID: 30301790). | 30301790 |
| ERBB2 L755S ERBB2 amp | Her2-receptor positive breast cancer | resistant | Lapatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ERBB2 (HER2) L755S was associated with reactivation of ERBB2 (HER2) signaling and acquired resistance to Tykerb (lapatinib) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification in culture and in xenograft models (PMID: 28487443). | 28487443 |
| ERBB2 E812K | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) E812K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). | 18413839 |
| ERBB2 D769H | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) D769H were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 E717K | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). | 18413839 |
| ERBB2 amp | lung cancer | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) treatment reduced viability of a lung cancer cell line harboring an ERBB2 (HER2) amplification in culture (PMID: 30674502). | 30674502 |
| ERBB2 V773M | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 E719G | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) E719G demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). | 18413839 |
| ERBB2 L785F | Advanced Solid Tumor | decreased response | Lapatinib | Preclinical | Actionable | In a preclinical study, transformed cells over expressing ERBB2 (HER2) L785F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). | 18413839 |
| ERBB2 V604_E619del | breast cancer | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited Erbb2 signaling and viability of transformed breast epithelial cells expressing ERBB2 (HER2) V604_E619del in culture (PMID: 31135266). | 31135266 |
| ERBB2 L755P | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L755P were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 L755P | Advanced Solid Tumor | resistant | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346). | 22046346 |
| ERBB4 E452K | melanoma | sensitive | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E452K in culture (PMID: 19718025). | 19718025 |
| PIK3CA E542K | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007). | 26627007 |
| PIK3CA H1047R | breast cancer | sensitive | Lapatinib | Preclinical | Actionable | In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007). | 26627007 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status |
|---|---|---|---|---|
| NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed |
| NCT00759642 | Phase II | Lapatinib | Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy | Terminated |
| NCT02559778 | Phase I | Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Recruiting |
| NCT01160211 | Phase III | Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | Active, not recruiting |
| NCT02551718 | Phase I | Bosutinib Irinotecan Romidepsin Busulfan Melphalan Nilotinib Crizotinib Cytarabine Mitoxantrone Dasatinib Pazopanib Paclitaxel Clofarabine Hydroxyurea Tretinoin Carfilzomib Nelarabine Bexarotene Pentostatin Everolimus Cabozantinib Mercaptopurine Methotrexate Cladribine Thioguanine Daunorubicin Ponatinib Etoposide Afatinib Gefitinib Gemcitabine Regorafenib Arsenic trioxide Trametinib Imatinib Erlotinib Dabrafenib Decitabine Axitinib Azacitidine Ruxolitinib Fludarabine Lapatinib Ceritinib Sirolimus Sorafenib Lomustine Sunitinib Cabazitaxel Temsirolimus Topotecan Bortezomib Pralatrexate | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia | Recruiting |
| NCT01868503 | Phase II | Lapatinib | Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer | Terminated |
| NCT01622868 | Phase II | Lapatinib | Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | Active, not recruiting |
| NCT01328054 | Lapatinib | A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval | Completed | |
| NCT00939523 | Phase II | Lapatinib | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | Completed |
| NCT00790816 | Phase I | Lapatinib + Paclitaxel Lapatinib Lapatinib + Trastuzumab Capecitabine + Lapatinib Lapatinib + Letrozole Capecitabine + Lapatinib + Oxaliplatin Gemcitabine + Lapatinib Docetaxel + Lapatinib Fluorouracil + Lapatinib + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Lapatinib + Leucovorin | Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents | Completed |
| NCT02101905 | Phase I | Lapatinib | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | Active, not recruiting |
| NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Active, not recruiting |
| NCT00863122 | Phase I | Lapatinib | Concentration and Activity of Lapatinib in Vestibular Schwannomas | Completed |
| NCT01427322 | Lapatinib | Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease | Terminated |
CKB BOOST